All CancersNCT00578162
A Study of Survivorship Service Capacities Among Health Care Agencies in New York City
An observational study of All Cancers, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
To describe the range of services available to cancer survivors in the NYC area. To determine organizations' need for assistance to enhance services for survivors. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- All Cancers
- What is being tested?
- we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER
- Type of treatment
- Lifestyle or therapy programme
- How many people
- Not given
- Where
- 1 siteUnited States
- Study dates
- Apr 2005to Apr 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: We assume that the collective network of cancer care and support services can be represented with data from no more than 300 New York City agencies, across all five boroughs. Theseagencies would include hospitals, clinical diagnostic centers, and community-based organizations.
Who may be able to join
- To be eligible to participate in the study, an agency must:
- Be a current provider of either:
- General health services (GHS), such as primary care, health education and wellness, mental health services, home health care, palliative care, or cancer screening and diagnosis;
- Cancer-specific medical treatments (CMT), such as cancer surgery, radiation, chemotherapy, hormonal therapy; experimental therapies; cancer pain and symptom management; rehabilitation services; post-treatment monitoring and surveillance; or prophylactic treatments, such as chemoprevention; or
- Any type of specialized 'post-cancer' or 'after-cancer' medical care or support services (SMC) (i.e., psychotherapeutic, relationship and family, psycho-educational,wellness and quality of life)
- Be located within the five boroughs of New York City
- Have been serving cancer patients for 12 months or longer, and
- Be willing and able to identify an English-speaking representative, 21 years of age or older as its designated key informant.
Who cannot join
- We will limit this study to provider agencies such as hospitals, diagnostic centers, clinics, health and human service agencies, and grassroots community organizations and public service settings that offer programs for cancer survivors. Independent practitioners or private practice settings will not be surveyed. Our survey questions are intended for major health services organizations and are not appropriate for private practices settings.
- We will use our screening questionnaire to determine where or not a given agency should be included or excluded from the study AGENCY SCREENER.
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
About this study
To describe the range of services available to cancer survivors in the NYC area.
To determine organizations' need for assistance to enhance services for survivors.
Read the detailed description
To describe the range of services available to cancer survivors in the NYC area.
To determine organizations' need for assistance to enhance services for survivors.
- Conditions
- All Cancers
- Being tested
- we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER
- Keywords
- Cancer, Survivors
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENERBehavioural
A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
| Study group | Role | What they receive |
|---|---|---|
| 1 | Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory. Receives: Behavioral: we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine agencies' need for assistance to enhance services for survivors.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2007 (estimated)
- Study startApr 2005
- Primary completionApr 2009
- Study completionApr 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for All CancersStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- NYS DEPT HEALTH CANCER SVC PRO
- Responsible party
- Sponsor
- Investigators
- David Loundsbury, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00578162
- Sponsor's protocol ID
- 05-048
- Status last verified
- Jan 2012
- First submitted
- 19 Dec 2007
- Last updated
- 9 Jan 2012
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Survivorship Service Capacities Among Health Care Agencies in New York City
- ClinicalTrials.gov ID
- NCT00578162
- Acronym / sponsor ID
- 05-048
- Conditions
- All Cancers
- Keywords
- Cancer, Survivors
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- NYS DEPT HEALTH CANCER SVC PRO
- Study start
- Apr 2005
- Primary completion
- Apr 2009 (actual)
- Study completion
- Apr 2009 (actual)
- First posted
- 21 Dec 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To describe the range of services available to cancer survivors in the NYC area.
To determine organizations' need for assistance to enhance services for survivors.
Detailed description
To describe the range of services available to cancer survivors in the NYC area.
To determine organizations' need for assistance to enhance services for survivors.
Study design
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Behavioral: we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENERData about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- We assume that the collective network of cancer care and support services can be represented with data from no more than 300 New York City agencies, across all five boroughs. Theseagencies would include hospitals, clinical diagnostic centers, and community-based organizations.
Key inclusion criteria (8 listed)
- To be eligible to participate in the study, an agency must:
Key exclusion criteria (2 listed)
- We will limit this study to provider agencies such as hospitals, diagnostic centers, clinics, health and human service agencies, and grassroots community organizations and public service settings that offer programs for cancer survivors. Independent practitioners or private practice settings will not be surveyed. Our survey questions are intended for major health services organizations and are not appropriate for private practices settings.
- We will use our screening questionnaire to determine where or not a given agency should be included or excluded from the study AGENCY SCREENER.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENERA cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory | Behavioural | 1 |
Primary outcome
To determine agencies' need for assistance to enhance services for survivors.
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2012.
- Memorial Sloan-Kettering Web SiteLink provided by the sponsor.
Related trials for All Cancers
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Loundsbury, PhD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of All Cancers, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine agencies' need for assistance to enhance services for survivors. (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2012.